bezafibrate has been researched along with Cardiac Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carmody, MW; Davidoff, AJ; Davidson, MB; Hintz, KK; Mason, MM; Podolin, DA; Ren, J; Wold, LE | 1 |
| Bar-Shalev, A; Bar-Shalom, R; Frenkel, A; Israel, O; Keidar, Z; Rispler, S; Strauss, HW; Weiler-Sagie, M | 1 |
2 other study(ies) available for bezafibrate and Cardiac Diseases
| Article | Year |
|---|---|
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.
Topics: Animals; Bezafibrate; Diabetes Mellitus, Type 2; Dietary Sucrose; Heart Diseases; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Male; Myocardial Contraction; Myocytes, Cardiac; Physical Conditioning, Animal; Physical Exertion; Rats; Rats, Wistar | 2004 |
PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake.
Topics: Adult; Aged; Aged, 80 and over; Aging; Benzodiazepines; Bezafibrate; Diabetes Mellitus; Drug Interactions; Female; Fluorodeoxyglucose F18; Heart; Heart Diseases; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardium; Positron-Emission Tomography; Radiopharmaceuticals; Thyroxine; Tomography, X-Ray Computed; Whole-Body Counting | 2007 |